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Numerous epidemiological and toxicological studies have indicated that res-
piratory infections are exacerbated following enhanced exposure to airborne
particulates. Surfactant protein A (SP-A) and SP-D form an important part
of the innate immune response in the lung and can interact with nanoparticles
to modulate the cellular uptake of these particles. We hypothesize that this
interaction will also affect the ability of these proteins to combat infections.
TT1, A549 and differentiated THP-1 cells, representing the predominant cell
types found in the alveolus namely alveolar type I (ATI) epithelial cells,
ATII cells and macrophages, were used to examine the effect of two model
nanoparticles, 100 nm amine modified (A-PS) and unmodified polystyrene
(U-PS), on the ability of SP-A and SP-D to neutralize influenza A infections
in vitro. Pre-incubation of low concentrations of U-PS with SP-A resulted in
a reduction of SP-A anti-influenza activity inA549 cells,whereas at higher con-
centrations there was an increase in SP-A antiviral activity. This differential
pattern of U-PS concentration on surfactant protein mediated protection
against IAV was also shown with SP-D in TT1 cells. On the other hand, low
concentrations of A-PS particles resulted in a reduction of SP-A activity in
TT1 cells and a reduction in SP-D activity in A549 cells. These results indicate
that nanoparticles can modulate the ability of SP-A and SP-D to combat viral
challenges. Furthermore, the nanoparticle concentration, surface chemistry
and cell type under investigation are important factors in determining the
extent of these modulations.1. Introduction
The rapid growth in the nanotechnology industry has led to concerns regarding
the potential health implications of nanomaterial exposures. The toxicological
impact of nanomaterials is particularly concerning in light of the evidence
which shows that airborne particulate matter (PM) is responsible for enhanced
morbidity and mortality from cardiopulmonary causes [1–4]. One of the
adverse respiratory outcomes following exposure to high PM levels is increased
incidence and severity of respiratory infections [5]. This is of particular concern
in young children and the elderly [6,7]. Pre-natal exposure to PM2.5 has been
shown to increase the incidence of recurrent pneumonia and acute bronchitis
in children in a concentration dependent manner. Moreover, incidences of
these pulmonary infections following exposure to PM2.5 were much higher in
children with asthma [8]. In children less than 1 year, every hour of exposure
to indoor PM2.5 above 100 mg m
23 led to a 7% increase in the risk of acute
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found in children of 1–2 years [9]. These indoor exposure
concentrations are common in developing countries where
ALRI accounts for around one in five of the deaths of children
under 5 years [10]. Pre-exposure to more than 33.3 mg m23
PM10 has also been shown to delay the resolution of respiratory
tract infections by around 20% in healthy infants [5]. Diesel
exhaust (DE) and diesel exhaust particulates (DEP) have been
shown to enhance and exacerbate influenza Avirus (IAV) infec-
tions inmice [11–14]. Furthermore, pre-exposure toDEandDEP
has been shown to increase respiratory syncytial virus (RSV)
infection and viral induced lung inflammation in mice in vivo.
Interestingly, this studyshoweda reduction in surfactantprotein
A (SP-A) expression during RSV infection following exposure to
DE [15]. In another study, the exposure of mice to DEP for six
months prior to IAV infection resulted in an increased incidence
of infection but did not alter mortality in IAV exposedmice [16].
The evidence surrounding the enhanced susceptibility to res-
piratory infections following particulate exposure relates to
ambientparticulatematter rather thanengineerednanoparticles.
However, these studies serve as useful guides to understand the
potential toxicological issues which may be faced following
exposure to engineered nanoparticles.
SP-A and SP-D are important innate immune molecules
found primarily in pulmonary surfactant, the lipoprotein sub-
stance found at the air–liquid interface in the alveoli of the
lungs. SP-A and SP-D are calcium-dependent lectin pattern
recognition molecules and belong to the subfamily known as
the ‘collectins’. The pulmonary collectins are oligomerized pro-
teins and play an integral role in the innate immune defence
of the lung. They recognize and bind specific carbohydrate
moieties on the surface of microorganisms and can act to neu-
tralize microbial challenge via agglutination and opsonization
[17–20]. SP-A and SP-D form a part of the defence against IAV
infection. SP-A and SP-D bind to haemagglutinin (HA), a sur-
face glycoprotein of IAV; this interaction directly inhibits
cellular infection by preventing the interaction of HA with
sialic acid containing receptors. SP-A and SP-D bind HA
through different mechanisms. HA binds to the partially sialy-
lated asparagine 187 residue in the carbohydrate recognition
domain of human SP-A; this interaction is calcium independ-
ent and is not antagonized by mannan [21–23]. SP-D binds
to glycosylation sites onHA and is classified as a b-type inhibi-
tor of influenza as this interaction is calcium-dependent and
SP-D is heat labile and resistant to degradation by neuramin-
idase (NA) [20]. SP-D is also able to bind to NA, the second
surface glycoprotein of IAV, and inhibit the release of progeny
virions from infected cells [23,24]. The binding of SP-A and
SP-D to IAV also aids the neutralization of IAV through the
agglomeration and opsonization of virions [25–27].
SP-A and SP-D have been reported to associate with nano-
particles and this interaction has been shown to alter the
cellular uptake of these nanoparticles [28–30]. Metal oxide
nanoparticles incubated in bronchoalveolar lavage (BAL)
have been shown to adsorb SP-A; the extent of this interaction
was shown to be dependent on the particle surface chemistry
[31]. The SP-A and SP-D interaction with magnetite particles
possessing different polymer coatings has also been investi-
gated. These studies have shown that both SP-A and SP-D
enhance the uptake by macrophages of magnetite particles
with hydrophobic and hydrophilic surface coatings. However,
SP-D enhanced the uptake of hydrophilic nanoparticles to a
greater extent than SP-A; whereas for hydrophobic particlesthe reverse was true [28,29]. Furthermore, it has been shown
that SP-D is removed from suspension when co-incubated
with carbon black particles [32].
It was therefore hypothesized that the interaction of SP-A
and SP-D with nanoparticles could lead to a deficiency in
these innate immune molecules and enhance susceptibility
to infection (figure 1). In order to test this hypothesis, an in
vitro infection model was used to determine the effect of
100 nm unmodified polystyrene (U-PS) and amine modified
polystyrene (A-PS) particles on the SP-A and SP-D mediated
neutralization of influenza virus. This was conducted in three
cell lines, TT1, A549 and differentiated THP-1 cells to reflect
the major cell types found in the alveolar epithelium,
namely the alveolar type I (ATI) and type II cells and the
alveolar macrophages.2. Material and methods
(a) Protein purification
SP-A and SP-D were purified from human bronchoalveolar
lavage (BAL). SP-A was purified using butanol extraction as
described previously [33]. SP-D was purified using affinity
chromatography and size exclusion chromatography [34].
(b) IAV propagation and purification
IAV H3N2 X79 was propagated in cell culture using MDCK cells
and purified on a discontinuous 30–60% sucrose gradient as
previously described [35]. Viral titre was determined using the
fluorescent focus assay and measured as fluorescent focus units
(FFU) ml21.
(c) Cell culture
TT1 cells were provided by Prof. T. Tetley, Imperial College
London, and were grown in DCCM1 media (Cellseco, Porton
Down, UK) containing 10% heat inactivated new born calf
serum, 100 units ml21 penicillin and 100 mg ml21 streptomycin,
2 mM L-glutamine (Invitrogen, UK) and 0.5 mg ml21 G418
(Sigma, UK) as described previously [36]. A549 cells were grown
in RPMI1640 (Invitrogen, UK) containing 10% fetal bovine
serum (FBS; Sigma, UK) and 100 units ml21 penicillin and
100 mg ml21 streptomycin. THP-1 cells were kindly provided by
Liku Tezera and were grown in RPMI1640 medium containing
10% heat inactivated FBS (PAA, UK) and 100 units ml21 penicillin
and 100 mg ml21 streptomycin. A549 and TT1 cells were routinely
subcultured every 2–3 days using trypsin. THP-1 cells grow in sus-
pension and were subcultured by diluting cell suspensions in
growth medium every 2–3 days to maintain cell density at
around 5  105–1.5  106 cells ml21.
(d) Nanoparticles
This study used fluorescent orange 100 nm A-PS (Sigma, UK) and
fluorescent green 100 nm U-PS (Polysciences, UK) nanoparticles.
The size distribution and zeta potentials of these nanoparticles in
Tris-buffered saline (TBS) with calcium has previously been
characterized and reported [30,37].
(e) IAV infection
A549 and TT1 cells (0.3 ml) were seeded at a density of 4.16 
105 ml21 in 48-well plates (Corning, UK). The cells were incubated
for 6 h in relevant growth medium then serum starved for 24 h in
serum-free (SF) RPMI. THP-1 cells were suspended at a concen-
tration of 4.16  105 cells ml21 in growth medium containing
10 nM phorbol 12-myristate 13-acetate (PMA). Cells were plated
SP-A
SP-D
NP
inhibition of
SP-A/D 
binding to IAV
(a)
(e)
(b) (c) (d)
IAV
infection inhibition of infection inhibition of
progeny virions
IAV
agglomeration 
inhibition of infection opsonization
infection
Figure 1. Hypothesis of nanoparticle (NP) sequestration of SP-A and SP-D enhancing IAV infection. (a) Influenza A virus (IAV) initiates infection through the binding
of the surface glycoprotein haemagglutinin (HA) to sialic acid containing receptors on the host cell. (b) Surfactant protein A (SP-A) and SP-D bind to HA and prevent
its interaction with sialic acid [20–23]. (c) SP-D binds neuraminidase on IAV surface and prevents the release of progeny virions from the host cell following
replication [23,24]. (d ) SP-A and SP-D act to agglomerate IAV which directly inhibits infection and also enhances the opsonization of IAV by professional phagocytes
such as macrophages [25–27]. (e) It is hypothesized that the interaction of SP-A and SP-D with NPs in the alveolar space will reduce their interaction with and
neutralization of influenza virus, and thereby enhance susceptibility to infection.
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a humidified atmosphere. PMAwas dissolved in dimethyl sulfox-
ide which was used as a vehicle control and kept at less than 0.1%
in all experiments. All cells were serum starved for 24 h in SF RPMI
prior to exposure to nanoparticle/IAV suspensions.
Particles were prepared at three times the final concentration in
TBS containing 5 mM calcium. SP-A, SP-D and bovine serum albu-
min (BSA) were also prepared in TBS with 5 mM calcium at three
times the final concentration.Equal volumes of nanoparticle suspen-
sionandprotein suspensionswere added to a 48-well plate, theplate
wasgently agitated and incubated at 378C for 1 h. IAVwasprepared
at three times the final concentration (2.23 105 FFU ml21) in TBS
with calcium and then added to the nanoparticle and protein sus-
pension.The inoculumwasthen incubated forafurtherhourat 378C.
The medium was removed from the serum starved cells
and replaced with the inoculum. The cells were then incubated
for 1 h at 378C 5% CO2 in a humidified atmosphere. The cells
were washed three times in SF RPMI and the cells were then
incubated in fresh SF RPMI (0.5 ml) for 18 h at 378C 5% CO2 in
a humidified atmosphere.
Following incubation, the cells were washed with calcium/
magnesium-free PBS and trypsinized for 5 min. The trypsin was
deactivated by adding a 10-fold excess of complete medium. The
cell suspension was centrifuged for 5 min at 400 g and the cell
pellet was resuspended in 1% formaldehyde in PBS and incubated
for 1 h at room temperature. The cells were resuspended in 1 ml
PBS then centrifuged at 400 g for 5 min. The pellet was then resus-
pended in 1 ml PBS with 0.3% triton (TrPBS) to permeabilize the
cell membranes, the cells were then centrifuged at 400 g for 5 min.
The cells were resuspended in TrPBS containing 1.5 mg ml21 of
mouse anti-influenza A nucleoprotein (Abcam, UK) and incubated
for 1 h at room temperature. The cells were washed (2  1 ml) in
TrPBS by centrifuging the sample at 400 g for 5 min. The cells
were resuspended in TrPBS containing 1 mg ml21 of goat anti-
mouse IgG secondary antibody coupled to allophycocyaninfluorophore and incubated for 1 h at room temperature. The cells
were then washed twice in TrPBS as above then resuspended in
100 ml of PBS. The percentage of cells infected with IAV was deter-
mined using a FACSAria: 10 000 cells were analysed per sample
and each experiment was conducted in duplicate.
( f ) Statistics
Relative infection rates were reported as mean values. Differences
between two treatments were determined using the Mann–
Whitney U-test. p-Values less than or equal to 0.05 were
considered statistically significant and were determined using
the Mann–Whitney U-test unless otherwise stated. Infection
rates were normalized for each experiment prior to analysis. The
ability of the particles to modify surfactant protein neutralization
was calculated using the following formula:
Relative change in IAV neutralization (%) =
B A
A
 
 100,
(2:1)
where B is the percentage of uninfected cells in the nanoparticle,
protein and IAV treatment, and A is the percentage of uninfected
cells in the appropriate IAV and protein control.3. Results
We have previously shown that SP-A and SP-D interact with
nanoparticles and that these interactions can alter particle
agglomeration anduptake byphagocytes such asmacrophages.
Here, we present for the first time the effect of nanoparticles on
the function of SP-A and SP-D. The effect of 100 nm cationic
A-PS and anionic U-PS nanoparticles on the ability of SP-A/
SP-D to neutralize IAV infection in vitro was examined in TT1,
A549 and differentiated THP-1 cell lines. These cells represent
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Figure 2. Effect of 100 nm U-PS on SP-A and SP-D mediated neutralization of influenza A infection. U-PS were pre-incubated with 5 mg ml21 SP-A prior to incubation
with IAV and treatment of (a) A549, (b) TT1 and (c) differentiated THP-1 cells. U-PS particles were pre-incubated with 0.4 mg ml21 SP-D prior to incubation with IAV and
treatment of (d ) A549, (e) TT1 and ( f ) THP-1 cells. Horizontal line represents mean of at least three independent experiments conducted in duplicate. Statistics determined
using Mann–Whitney U-test where *p  0.050 compared to relative infection in particle free protein control; #p  0.050 versus IAV alone.
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epithelial cells, ATII cells and macrophages [38].
In this study, concentrations of 5 mg ml21 SP-A and
0.4 mg ml21 SP-Dwerechosenwhichwere shownto induceasub-
maximal inhibition of IAV infection (data not shown). Thus any
nanoparticle induced modulation in the ability of these proteins
to neutralize infection could be detected. Nanoparticles were
initially pre-incubated with proteins for 1 h, then influenza was
added to the inoculum and incubated for a further hour. This
procedurewaschosen inorder to test thehypothesis thatnanopar-
ticles would sequester surfactant proteins and thereby attenuate
their ability to neutralize infection. Incubations were conducted
in TBS containing 5 mMcalcium, sufficient for the lectin function-
ality of the collectins. This buffer was shown not to alter cell
viability or influenza infection rates compared with SF media
(data not shown). The nanoparticles used in these experiments
have previously been thoroughly characterized [30,37].
(a) Effect of U-PS on IAV infection
The effects of U-PS at concentrations of 0.0016–5 cm2 ml21
(0.0028–8.8 mg ml21) on IAV infection in the three cell types
are summarized in figure 2 and the electronic supplementary
material, table S1. The pre-incubation of 100 nm U-PS with
IAVhadnosignificant effect on IAV infection inA549 anddiffer-
entiated THP-1 cells at any of the nanoparticle concentrations
studied. InTT1cells, thepre-incubationof100 nmU-PSparticles
(0.04 cm2 ml21) with IAV resulted in a significant 7.3%
reduction in infection compared with IAV alone (p ¼ 0.037).
(b) Effect of U-PS on SP-A/D-mediated IAV
neutralization
In A549 cells, U-PS particles had differential effects at high
and low doses on the ability of SP-A to neutralize IAV infection(figure 2a–c). There were significant 8.0 and 8.6% increases in
relative infection rates in A549 cells following pre-incubation
of SP-A with 0.0016 and 0.04 cm2 ml21 U-PS compared with
SP-A in the absence of particles (p ¼ 0.050). These differences
represented 23.2 and 24.9% relative decreases in the efficacy
of SP-A to neutralize IAV infection (see equation (2.1)).
The pre-incubation of 5 cm2 ml21 U-PS with SP-A resulted
in a significant 16.7% reduction in IAV infection compared
with the IAV and SP-A control in A549 cells (p ¼ 0.050).
This represented a 48.4% increase in the antiviral activity
of SP-A.
In TT1 cells, U-PS particles also had differential effects at
high versus low concentrations on SP-D-mediated IAV neutral-
ization (figure 2e). The pre-incubation of 0.04 cm2 ml21 U-PS
with SP-D resulted in a significant 18.7% increase in IAV infec-
tion compared with the SP-D and IAV control (p ¼ 0.050). This
represented a 46.9%decrease in the ability of SP-D to neutralize
IAV infection in this cell line. The highest concentration of U-PS
studied (5 cm2 ml21) resulted in a significant 43.8% reduction
in relative infection rates compared with the absence of U-PS
( p ¼ 0.050). This signifies a 109.8% relative increase in the
inhibition of infection rates compared with SP-D.
In A549 and THP-1 cells, the pre-incubation of 5 cm2 ml21
U-PS with SP-D resulted in significant 30.8 and 22% reductions
in infection compared with SP-D and IAV alone (p ¼ 0.021).
These represent 55.7 and 69.6% relative increases in the
inhibition of IAV infection over SP-D alone (figure 2d,f ).
(c) Effect of A-PS on IAV infection
The effects of A-PS on IAV infection are summarized in figure 3
and the electronic supplementary material, table S2. In A549
and TT1 cells, 100 nm A-PS at 5 cm2 ml21 resulted in signifi-
cant 33.2 and 19.8% reductions in IAV infection (p ¼ 0.014
and p ¼ 0.005).
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Figure 3. Effect of 100 nm A-PS on SP-A and SP-D mediated neutralization of influenza A infection. A-PS were pre-incubated with 5 mg ml21 SP-A prior to
incubation with IAV and treatment of (a) A549, (b) TT1 and (c) differentiated THP-1 cells. A-PS particles were pre-incubated with 0.4 mg ml21 SP-D prior
to incubation with IAV and treatment of (d ) A549, (e) TT1 and ( f ) THP-1 cells. Horizontal line represents mean of at least three independent experiments conducted
in duplicate. Statistics determined using Mann–Whitney U-test where *p  0.050 compared to relative infection in particle free protein control; #p  0.050 versus
IAV alone.
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neutralization
InTT1 cells, 0.04 cm2 ml21A-PSparticlespre-incubatedwithSP-
A resulted in an 11% significant increase in IAV infection com-
pared with SP-A in the absence of particles (figure 3b). This
represents a 29.7% reduction in the antiviral efficacy of SP-A,
whereas in A549 cells, pre-incubation of 0.0016 cm2 ml21 A-PS
with SP-D resulted in a 8.1% increase in IAV infection compared
with the SP-D control (figure 3d). This differencewas statistically
significant with an associated p-value of 0.043 and represents a
13.0% reduction in the capability of SP-D to neutralize IAV
infection.(e) Effect of bovine serum albumin and nanoparticles
on IAV infection
BSAwas used to determine the effect of a non-specific protein
corona on influenza infection in these experiments. In A549,
TT1 and THP-1 cells, the pre-incubation of BSA with
0.0016–5 cm2 ml21 U-PS or A-PS had no significant effect
on IAV infection compared with the protein and IAV control
(electronic supplementary material, figure S1).4. Discussion
Exposure to airborne particulatematter has beenwidely shown
to be associatedwith increased incidence and altered resolution
of respiratory infections [5–7,15,16]. However, the mechanisms
behind this susceptibility remain poorly understood. We have
previously shown that polystyrene nanoparticles can interact
with SP-A and SP-D and that this interaction can alter nanopar-
ticle cellular uptake [30,37]. It was therefore hypothesized that
nanoparticles would inhibit the ability of these collectins toneutralize viral challenges through sequestering the protein to
the nanoparticle surface. Here, we show for the first time that
nanoparticles can modulate the ability of the innate immune
molecules SP-A and SP-D to neutralize in vitro viral infection.
This modulation was dependent on the protein, nanoparticle,
nanoparticle concentration and cell type under investigation.
This could be an important step in establishing themechanisms
behind the increased susceptibility to infection following
particle exposure.
This study evaluated the effect of unmodified and surface
modified 100 nm polystyrene particles on the surfactant
protein mediated neutralization of influenza infection in
three cell lines. These nanoparticles were chosen as we have
previously shown that SP-A and SP-D interact with these par-
ticles and result in differential uptake by alveolar macrophages
[30,37]. The cell lines were chosen to reflect those found within
the alveolus, namely TT1, A549 and THP-1 cells as models for
ATI, ATII and macrophages, respectively. ATI cells are large,
thin squamous cells that comprise 94% of the alveolar surface
area but constitute only a third of the total number of alveolar
epithelial cells [38]. ATII cells make up more than 60% of
the number of epithelial cells within the alveolus and are
responsible for the production and recycling of pulmonary
surfactant [39]. A549 cells were derived from a lung adenocar-
cinoma and were originally considered to be a model for ATII
cells [40–42]. However, other investigators have shown that as
they do not possess many of the typical ATII phenotypic
characteristics, such as surfactant production or alkaline phos-
phatase activity, they are not a good ATII model [36,43,44].
Despite these findings, A549 cells are one of the main cell
types used to investigate the toxicity of nanoparticles on alveo-
lar epithelial cells and have therefore been included in this
study [45–49].
Low concentrations of unmodified polystyrene nanoparti-
cles resulted in a reduction in the ability of surfactant proteins
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A549 cells or SP-D in TT1 cells, whereas at higher U-PS con-
centrations an increase in the surfactant protein mediated IAV
neutralization was reported. Interestingly, low concentrations
of A-PS also inhibited the neutralization of IAV infection by
SP-A in TT1 cells and with SP-D in A549 cells (i.e. the recip-
rocal to the effect with U-PS). This differential effect of
nanoparticle concentration on the modulation of surfactant
protein mediated IAV neutralization by A-PS and U-PS
could suggest a protein sequestration mechanism at low par-
ticle concentrations and a particle agglomeration mechanism
at higher concentrations. As the amount of particles in the
in vitro system increase, the amount of ‘available protein’
in solution will decrease as the particles sequester the surfac-
tant protein. As the concentration of nanoparticle increases
further, the effect of protein sequestration on influenza infec-
tion is minimized and then reversed by the agglomeration of
nanoparticle and influenza complexes. This shows that low
in vitro nanoparticle concentrations can lead to deficiencies in
SP-A and SP-D, which in turn can enhance the susceptibility
to influenza infection. The implications of this could extend
far beyond virus neutralization by these collectins. The func-
tions of SP-A and SP-D are multifaceted and the perturbation
of their function has been linked to the pathogenesis of a
number of diseases (e.g. chronic obstructive pulmonary dis-
ease (COPD) and idiopathic pulmonary fibrosis). Further
work is necessary to determine the effect of nanoparticles on
the other functions of SP-A and SP-D.
The highest concentration of U-PS particles (5 cm2 ml21)
tended to enhance the IAV neutralizing activity of both SP-A
and SP-D in each of the three cell lines studied, except for SP-
A with THP-1 cells. In order to establish whether this was
due to the enhanced agglomeration of the nanoparticle–
protein complex or through direct interactions of the complex
with the cells under investigation, a haemagglutination inhi-
bition assay was conducted. The results of this assay showed
that at the highest concentration studied, the nanoparticles
themselves, in the absence of protein and virus, could result
in the apparent haemagglutination of red blood cells (data not
shown). We therefore cannot exclude that, at the 5 cm2 ml21
concentration, U-PS particles can interact directly with cells
and this may, by squelching the system with high concen-
trations of nanoparticles, contribute to the observed enhanced
protective effect of the surfactant proteins. The concentration
of 5 cm2 ml21 would therefore be the upper limit of U-PS
concentrations that could be tested in in vitro infection models.
In a previous study, acute high doses of carbon black
resulted in a protective effect in mice against Streptococcus
pneumonia [50]. The dose used in that study, however, was
1000 mg/mouse given in two equal installations 3 days apart
and represents a dose far in excess of environmentally relevant
concentrations. This study shows that concentration is a critical
factor in determining the effect of nanoparticles in infection
models and that acute doses are not representative of chronic
or low dose effects.
BSAwas used in this study to examine the effect of a non-
specific protein corona on IAV infection rates. This was done to
determine whether any effects observed with surfactant pro-
teins were due to surfactant protein specific effects or due to
the presence of protein. BSA had no significant effect on IAV
infection in anyof the cells studied. The incubation ofU-PS par-
ticles with BSA had no significant effect on IAV infection at any
of the concentrations or cell lines tested.A-PS particles resulted in a reduction in IAV infection at
the highest concentration studied in A549 and TT1 cells.
This was not attributable to cell toxicity at this concentration
as no reduction in cell viability was observed using the MTT
assay (data not shown). Amine particles have been proposed
to act as a proton sponge within the lysosome, resulting in
enhanced proton pump activity, lysosomal swelling and rup-
ture [51]. The acidification of the endosome is an important
step in virus entry as it initiates the conformational change
in the HA and the fusion of viral and endosomal membranes
[52,53]. This could explain the reduction of IAV infection at
the highest A-PS concentration studied, as the amine particles
could be perturbing the acidification of the endosome and
inhibiting IAV release and replication within the cell. How-
ever, other mechanisms may also be involved. For instance,
the envelope of the IAV virion is derived from the host cellu-
lar membrane. Amine particles have been shown to bind
anionic patches on cell membranes and this interaction has
been shown to cause membrane disruptions [54,55]. It is
therefore possible that A-PS particles could be binding to the
lipid virion envelope and either disrupting the integrity of
the virion or sterically hindering its attachment to the cell mem-
brane. As the A-PS particles self-agglomerate at physiological
temperatures, the IAV could become entrapped within these
agglomerates, thereby inhibiting virus attachment and entry
into the cell [37]. This may be the reason that the effect of high
concentrations of A-PS on IAV infection is less pronounced
with the THP-1 cells, as phagocytes preferentially internalize
larger particles [56]. Interestingly, in preliminary experiments
high concentrations of U-PS particles (50 cm2 ml21) were
shown to inhibit IAV infection in A549 cells (data not shown).
Gold nanoparticles have also been previously shown to inhibit
HIV-1 infection through binding the surface viral glycoprotein
(gp120) and inhibiting its attachment with CD4 cells [57].
The binding of these polystyrene nanoparticles to HA should
therefore be investigated.
This study used four concentrations of nanoparticles over
a 3125-fold dilution range. These concentrations were chosen
in order to establish the effect of lowandhigh doses of nanopar-
ticles in the developed in vitro system. While this concentration
range showed nanoparticle modulation of SP-A and SP-D
activity, it also showed that this modulation was highly suscep-
tible to nanoparticle concentration with perhaps only a narrow
window of efficacy. In order to establish the extent of the nano-
particle modulatory concentration range further, in vitro work
using this system is required.
Individuals with existing respiratory conditions such as
COPD show reduced levels of pulmonary SP-A and SP-D
levels due to their translocation to the systemic circulation.
These individuals show enhanced susceptibility to infections,
especially following enhanced PM exposure. The sequestra-
tion of SP-A and SP-D by particles within the alveolus
could therefore play an important role in the pathogenesis of
this susceptibility. The results from this study show that nano-
particles can sequester surfactant proteins and that this
sequestration can reduce surfactant protein function. However,
there were a number of factors which affected the ability of the
nanoparticle to alter protein function. A key determining
factor was the concentration of the nanoparticles used in the
study. Surfactant protein function was only impinged at
the lower two concentrations used in this study. At higher con-
centrations, either no effect was observed or nanoparticles
enhanced surfactant protein activity. Many toxicity studies use
rstb.royalsocietypublishing.org
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substances; this practice seems to be particularly prevalent in
nanotoxicology. However, this study shows fundamental differ-
ences betweenhigh (acute) and low (chronic) concentrations. The
highest concentration used in this studywas 5 cm2 ml21which is
equivalent to approximately 8.8 mg ml21. Even this dose is
modest compared with other in vitro nanotoxicology studies,
which typically range between 10 and 300 mg ml21 [54,58–61].
The low concentrations used this study therefore represent
several times less than those used in conventional nanotoxico-
logy studies. The low doses used in this study (0.0028 and
0.07 mg ml21 for 0.0016 and 0.04 cm2 ml21, respectively) are
more likely to represent chronic exposurewhereby the surfactant
system is gradually depleted, rather than acute concentrations
where the surfactant is rapidly overwhelmed.
These results demonstrate the difficulties in using acute
high concentrations in vitro and extrapolating the results
towards environmentally relevant concentrations associated
with chronic exposure. This model is the first step indeveloping a chronic in vitro cell culture exposure system. In
future, the model will be developed further to determine the
effect of chronic long-term pre-exposure to nanoparticles on
influenza infection and surfactant protein mediated neutral-
ization. This study highlights the urgent need for further
investment and research into SP-A and SP-D sequestration by
nanoparticles and the resulting effects of this sequestration
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